Skip to main content

Controversies around lithium

Guest Editors:
Michael J. GitlinUniversity of California at Los Angeles, USA  
Michael BauerTechnische Universität Dresden, Germany

Submission Status: Open   |   Submission Deadline: 31 December 2023


The International Journal of Bipolar Disorders is calling for submissions to our Collection on Controversies around lithium. Without a doubt, lithium is an essential medication for people with bipolar disorders and represents the most valuable treatment option in the prophylactic treatment for more than seven decades. From a historical perspective, since its establishment in the field of clinical psychopharmacology in the mid of the 20th century, several new aspects have been discovered in basic and clinical research, including anti-suicidal and antidepressant effects when used as an augmentation strategy. There is ample evidence that the capability of lithium long-term treatment to reduce the suicidal risk distinguishes it from the other mood stabilizers used in bipolar disorder. However, although studied for decades, there are still a lot of open questions around lithium. This thematic series will be centred on unanswered concerns. The ultimate goal is to assist in unravelling the biological mechanisms behind lithium’s clinical effects in order to enhance diagnosis and therapy of bipolar disorders.

Image credit: Michael Bauer

Meet the Guest Editors

Back to top

Michael J. Gitlin: University of California at Los Angeles, USA

Michael J. Gitlin, MD, is Distinguished Professor of Clinical Psychiatry at the University of California at Los Angeles School of Medicine. He is currently Director of the Adult Division in the Department of Psychiatry, Medical Director of the Neuropsychiatric Behavioral Health Services, and Director of the Mood Disorders Clinic. He is the author of many scientific articles and book chapters as well as five books, including “The Essential Guide to Lithium Treatment” with Michael Bauer. Among his awards are: Distinguished Educator Award in Teaching from the UCLA Department of Psychiatry (1999) and the Leonard Tow Humanism in Medicine award from the Geffen School of Medicine at UCLA (2010).

Michael Bauer: Technische Universität Dresden, Germany

Michael Bauer, MD, PhD, is Professor of Psychiatry and Chair of the Department of Psychiatry and Psychotherapy at the Medical Faculty and Director of the Psychiatric Hospital of the Carl Gustav Carus University Hospital, Technische Universität Dresden. He is project coordinator of the National consortium for the German Treatment Guidelines for Bipolar Disorder, leads the National Research Network on Bipolar Disorder “BipoLife”, and is chair of the International Society for Bipolar Disorders (ISBD) Task Force “Role of Lithium in Bipolar Disorders”. From 2002-2022 he was President of the International Group for the Study of Lithium-Treated Patients (IGSLi). Together with Michael J. Gitlin he authored the textbook “The Essential Guide to Lithium Treatment” and is founder and editor-in-chief of the International Journal of Bipolar Disorders since 2013.

About the Collection

The International Journal of Bipolar Disorders is calling for submissions to our Collection on Controversies around lithium. 

Without a doubt, lithium is an essential medication for people with bipolar disorders and represents the most valuable treatment option in the prophylactic treatment for more than seven decades. Amazingly, this ubiquitous occurring trace element can be considered the psychotropic medication with the longest clinical application in modern psychopharmacology. From a historical perspective, since its establishment in the field of clinical psychopharmacology in the mid of the 20th century, several new aspects have been discovered in basic and clinical research, including anti-suicidal and antidepressant effects when used as an augmentation strategy. There is ample evidence that the capability of lithium long-term treatment to reduce the suicidal risk distinguishes it from the other mood stabilizers used in bipolar disorder. Furthermore, basic research has solidly demonstrated in the previous decade that lithium possesses neuroprotective properties in animals and in vitro, and likely in humans as well when used prophylactically in people with bipolar disorder. 

However, although studied for decades, there are still a lot of open questions around lithium. Examples include: Does lithium have the potential to prevent dementia if used in very early stages of the disease or even prophylactically in people at high familiar risk? Does lithium have acute anti-suicidal effects? Why do the prescription rates decline in many countries given the extraordinary evidence of its effectiveness in the maintenance treatment of bipolar disorders and recommendations in international treatment guidelines? Does lithium long-term treatment reduce the risk of developing cancer? And being infected with the SarsCoV2 virus? Why does lithium in drinking water, where it appears as a trace element, reduce the suicide rate, although the concentrations are much higher when used as a medication to treat bipolar disorders? Are there ways to better predict the population among long-term lithium users who develop chronic renal disease? What are the biological mechanisms leading to the profound effectiveness to prevent episodes of mania and depression? 

This thematic series, which intends to approach some of these unanswered questions about lithium from a broad and multidisciplinary perspective, will be centred on these and other unanswered concerns. The ultimate goal is to assist in unravelling the biological mechanisms behind lithium’s clinical effects in order to enhance diagnosis and therapy of bipolar disorders.

  1. The impact of long-term lithium treatment on weight gain has been a controversial topic with conflicting evidence. We aim to assess reporting of weight gain associated with lithium and other mood stabilizers c...

    Authors: Waldemar Greil, Mateo de Bardeci, Bruno Müller-Oerlinghausen, Nadja Nievergelt, Hans Stassen, Gregor Hasler, Andreas Erfurth, Katja Cattapan, Eckart Rüther, Johanna Seifert, Sermin Toto, Stefan Bleich and Georgios Schoretsanitis
    Citation: International Journal of Bipolar Disorders 2023 11:34
  2. For over half a century, it has been widely known that lithium is the most efficacious treatment for bipolar disorder. Yet, despite this, its prescription has consistently declined over this same period of tim...

    Authors: Gin S. Malhi, Erica Bell, Maedeh Jadidi, Michael Gitlin and Michael Bauer
    Citation: International Journal of Bipolar Disorders 2023 11:30
  3. Lithium is the preferred treatment for pregnant women with bipolar disorders (BD), as it is most effective in preventing postpartum relapse. Although it has been prescribed during pregnancy for decades, the sa...

    Authors: Noralie N. Schonewille, Pleun A. Terpstra, Maria E. N. van den Heuvel, Maria G. Van Pampus, Odile A. van den Heuvel and Birit F. P. Broekman
    Citation: International Journal of Bipolar Disorders 2023 11:24

Submission Guidelines

Back to top

This Collection welcomes submission of original research, reviews, and short communications. Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process, under the section additional information, you will be asked whether you are submitting to a Collection, please select "Controversies around lithium" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Guest Editors have no competing interests with the submissions which they handle through the peer-review process. The peer-review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.